Format

Send to

Choose Destination
See comment in PubMed Commons below
Liver Int. 2013 Feb;33 Suppl 1:105-10. doi: 10.1111/liv.12066.

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Author information

1
Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23226, USA. Mitchell_shiffman@bshsi.org

Abstract

The current standard of care (SOC) for patients with chronic HCV genotype 1 is a combination of either boceprevir or telaprevir with peginterferon (PEG-IFN) and ribavirin (RBV). Although it is effective in a high percentage of patients, this treatment is associated with significant adverse events (AEs). The next generation of protease inhibitors, simeprevir and faldaprevir, will also be used with PEG-IFN/RBV. Interferon-free therapy with sofosbuvir appears promising and on the horizon for patients with genotypes 2 and 3, but may still be many years away for patients with HCV genotype 1. The factors which should be considered when deciding whether to treat a patient with HCV and mild fibrosis with the current SOC now, or to delay treatment until less toxic and/or more effective therapy is available is discussed.

PMID:
23286853
DOI:
10.1111/liv.12066
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center